Letairis® (ambrisentan) logo
For HCPs

Letairis (ambrisentan) is a prescription medicine used to treat pulmonary arterial hypertension (PAH), which is high blood pressure in the arteries of the lungs.

Letairis + tadalafil do more together than either alone

See the study results for combination therapy

The AMBITION trial was designed and conducted by doctors to study the use of Letairis and tadalafil together to see if combining the two drugs is more effective than using either drug alone. These drugs work to reduce the blood pressure in the lungs of patients with PAH in different ways.

In the AMBITION trial, a total of 605 patients who were classified to have World Health Organization (WHO) Functional Classes II–III PAH participated. The patients, who had not been previously treated for PAH, were randomly assigned to specific treatment: 302 patients received combination Letairis + tadalafil; 152 patients received Letairis alone; and 151 patients received tadalafil alone. On average, patients were on treatment for 1.5 years.

When Letairis and tadalafil were taken together, greater benefits were seen in the following 3 areas:

Walk

Improve 6-minute walk test

Patients nearly doubled their ability to walk farther

After 24 weeks, improvements in how far patients could walk in 6 minutes were:

  • 43 meters (141 feet) with Letairis + tadalafil
  • 23 meters (75.5 feet) with Letairis alone
  • 22 meters (72 feet) with tadalafil alone

The trial measured the patients’ ability to exercise using the 6-Minute Walk Test (6MWT: how far a patient can walk in 6 minutes). The 6MWT was measured before patients received any treatment and again at 24 weeks.

Disease Progression

Reduce your risk of PAH worsening

Patients were much less likely to have their PAH get worse*

The primary goal of the trial was to see if patients taking Letairis and tadalafil together were less likely to have their disease get worse (also referred to as disease progression). The trial looked at 3 ways a patient's PAH could get worse:

  • If they had a serious event, for example, needing to go to the hospital for PAH
  • If they had trouble walking and doing daily activities for more than 2 weeks
  • If they had trouble walking for more than 2 weeks and trouble doing daily activities for more than 6 months

Differences between the treatment groups were assessed after 105 of these events occurred.

*Only 20% of patients who took combination therapy had their disease get worse versus 35% of patients who took Letairis alone and 30% with tadalafil alone.

Hospitalization

Reduce PAH hospitalizations

Patients were much less likely to be hospitalized for worsening PAH†

†Only 8% of patients taking combination therapy were hospitalized for worsening PAH versus 22% of patients taking Letairis alone and 15% of patients taking tadalafil alone.

tips icon

Want to stay on branded Letairis?
Click here to learn more

TAP FOR IMPORTANT SAFETY INFORMATION INCLUDING AN IMPORTANT WARNING ON SERIOUS BIRTH DEFECTS IF TAKEN DURING PREGNANCY.
TAP FOR IMPORTANT SAFETY INFORMATION INCLUDING AN IMPORTANT WARNING ON SERIOUS BIRTH DEFECTS IF TAKEN DURING PREGNANCY.